Lisa A. Conte

CIK: 0001008377

Transaction Breakdown

Open Market Buys (P)2 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

JAGX

Jaguar Health, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

JAGX
Jaguar Health, Inc.
Dec 11, 2025
Award(A)
Direct
28.6K shares-
JAGX
Jaguar Health, Inc.
Jun 24, 2025
Award(A)
Warrant to Purchase Common Stock
Direct
18.3K shares-
JAGX
Jaguar Health, Inc.
Jun 24, 2025
Disposition(D)
Convertible Promissory Note
Direct
9K shares at avg. $50000.00-
JAGX
Jaguar Health, Inc.
Jun 24, 2025
Award(A)
Convertible Promissory Note
Direct
9.5K shares at avg. $50000.00-
JAGX
Jaguar Health, Inc.
May 17, 2025
Exercise(M)
Direct
2 shares-
JAGX
Jaguar Health, Inc.
Mar 31, 2025
Purchase(P)
Warrant to Purchase Common Stock
Direct
9K shares-
JAGX
Jaguar Health, Inc.
Mar 31, 2025
Purchase(P)
Convertible Promissory Note
Direct
9K shares at avg. $50000.00-
JAGX
Jaguar Health, Inc.
Oct 8, 2024
Award(A)
Direct
16.5K shares-

		Type	Shares	Price		Ownership
Dec 11, 2025	JAGX Jaguar Health, Inc.	Award(A)	28,592	-	$0	Direct
Jun 24, 2025	JAGX Jaguar Health, Inc.	Award(A) Warrant to Purchase Common Stock	18,262	-	-	Direct
Jun 24, 2025	JAGX Jaguar Health, Inc.	Disposition(D) Convertible Promissory Note	9,000	$50000.00	-	Direct
Jun 24, 2025	JAGX Jaguar Health, Inc.	Award(A) Convertible Promissory Note	9,462	$50000.00	-	Direct
May 17, 2025	JAGX Jaguar Health, Inc.	Exercise(M)	2	-	-	Direct
Mar 31, 2025	JAGX Jaguar Health, Inc.	Purchase(P) Warrant to Purchase Common Stock	9,000	-	-	Direct
Mar 31, 2025	JAGX Jaguar Health, Inc.	Purchase(P) Convertible Promissory Note	9,000	$50000.00	-	Direct
Oct 8, 2024	JAGX Jaguar Health, Inc.	Award(A)	16,503	-	$0	Direct

1-8 of 8 transactions

About CONTE LISA A

CONTE LISA A (SEC CIK 0001008377) files insider reports with the SEC as Director of Jaguar Health, Inc. (JAGX).

Signal8 holds 5 ownership filings by CONTE LISA A, all Form 4s, filed between Oct 10, 2024 and Jan 21, 2026. Those filings report 8 transactions, from Oct 8, 2024 to Dec 11, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on CONTE LISA A's filings is in SAN FRANCISCO, CA.

Recent filings by CONTE LISA A

Dec 11, 2025: Grant or award of JAGX shares (Form 4, code A).
Jun 24, 2025: Grant or award of JAGX derivative securities (Form 4, code A).
Jun 24, 2025: Disposition to issuer transaction of JAGX derivative securities (Form 4, code D).
Jun 24, 2025: Grant or award of JAGX derivative securities (Form 4, code A).
May 17, 2025: Option exercise of JAGX shares (Form 4, code M).

Other insiders filing for Jaguar Health, Inc. (JAGX)

MICEK JOHN, Director
King Steven R.
Wolin Jonathan S.
Chaturvedi Pravin R, Chief Scientific Officer
BOCHNOWSKI JAMES J, Director
Siegel Jonathan B., Director

How to read Form 4 transaction codes